Clinical value of ribs removal for treating middle-late stage primary liver cancer using HIFU plus TACE

JIN Cheng-bing; et al

您当前的位置：

首页 >

文章列表页 >

Clinical value of ribs removal for treating middle-late stage primary liver cancer using HIFU plus TACE

更新时间：2024-01-17

- Clinical value of ribs removal for treating middle-late stage primary liver cancer using HIFU plus TACE
- Journal of Chongqing Medical University Vol. 34, Issue 4, Pages: 475-478(2009)
- 作者机构：
  
  1. 重庆医科大学附属第二医院肿瘤中心
  2. 重庆医科大学生物医学工程系
- 作者简介：
- 基金信息：
- DOI：
  CLC： R735.7
- Published：2009，
扫描看全文
[1]金成兵,朱辉,王智彪,张炼,黎克全,周昆,杨炜,彭松,冉立峰.肋骨切除术在HIFU联合TACE治疗中晚期肝癌中的临床价值[J].重庆医科大学学报,2009,34(04):475-478.

JIN Cheng-bing, et al. Clinical value of ribs removal for treating middle-late stage primary liver cancer using HIFU plus TACE. [J]. Journal of Chongqing Medical University 34(4):475-478(2009)
[1]金成兵,朱辉,王智彪,张炼,黎克全,周昆,杨炜,彭松,冉立峰.肋骨切除术在HIFU联合TACE治疗中晚期肝癌中的临床价值[J].重庆医科大学学报,2009,34(04):475-478. DOI：

JIN Cheng-bing, et al. Clinical value of ribs removal for treating middle-late stage primary liver cancer using HIFU plus TACE. [J]. Journal of Chongqing Medical University 34(4):475-478(2009) DOI：

摘要

目的:探讨肋骨切除术在高强度聚焦超声（Hihg intensity focused ultrasound

HIFU）联合经导管动脉栓塞化疗（Tran-scatheter arterial chemoembolization

TACE）治疗中晚期肝癌中的临床价值。方法:68例右叶中晚期肝癌分为肋骨切除组（36例

43病灶）和非肋骨切除组（32例

40病灶）

随访两组患者HIFU联合TACE后的疗效

并进行比较。结果:总平均随访（11.9±11.4）月

两组中位生存期及1、2年生存率分别依次为13月、52.3%、21.8%与12月、46.8%、17.6%

两组比较无统计学意义（P=0.8155）;其病灶完整消融率和消融体积>80%比例分别依次为46.5%、79.1%与37.5%、67.5%

两组比较无统计学意义（P>0.05）。结论:肋骨切除术不能有效提高HIFU联合TACE治疗中晚期肝癌的疗效。

Abstract

Objective:To investigate the clinical value of ribs removal for treating middle-late stage primary liver cancer using high intensity focused ultrasound(HIFU)plus transcatheter arterial chemoembolization(TACE).Methods:68 middle-late stage patients with primary liver cancer were divided into ribs removal group(36 patents with 43 tumors)and non-ribs removal group(32 patients with 40 tumors).All patients received TACE and HIFU sequentially.Follow up the patients’survival and tumorablation results after TACE and HIFU.The median time

survival rates of 1-year and2-year

the rates of complete ablation and larger than 80%ablation volume were compared between two groups.Results:The average follow-up time of all patients were 11.9±11.4 months.The median time

1-year and 2-year survival rates in ribs removal group and non-ribs removal group were 13 months

52.3%

21.8%and 12months

46.8%

17.6%respectively.There was no significant difference of the survival between two group(sP=0.8155

log-rank tes)t.The rates of complete ablation and larger than 80%ablation volume in two groups were 46.5%

79.1%and 37.5%

67.5%respectively.There were no significant difference of the rates between two group(sP>0.05

Chi-square test).Conclusion:Ribs removal can not improve the effects of HIFU plus TACE in the treatment of middle-late stage primary liver cancer significantly.

关键词

肋骨切除术HIFUTACE肝癌疗效

Keywords

Ribs removalHighintensity focused ultrasound(HIFU)Transcatheter arterial chemoembolization(TACE)Primary livercancerEffect

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Effect of domestic glutathione treatment in the alcoholic liver disease

Clinical effect of montelukast combined salmeterol and fluticasone propionate dry powder in children with moderate to severe asthma

Stapled hemorrhoid treatment of mucous membrane of circumcision experience of 75 cases of hemorrhoids translated text

Related Author

赵有蓉

张定凤

曾维群

唐宝璋

李兆福

游晶

吕琳

陈压西

Related Institution

重庆医科大学肝炎研究所,重庆医科大学肝炎研究所,重庆医科大学肝炎研究所,昆明医学院第一医院传染科,昆明医学院第二医院消化科,昆明医学院第一医院传染科,昆明医学院第二医院消化科,重庆医科大学肝炎研究所重庆　400010,重庆　400010,重庆　400010

650000,昆明　650000,昆明　650000,重庆

Department of Internal Midecine,the Children Branch,Chongqing Three Gorges Central Hospita

Department of General Surgery,Bazhong Central Hospital of Sichuan Province

⁰